The approval to initiate a first-in-human trial is a significant pipeline catalyst for EDIT-401, but the stock remains a binary event stock. Watch for initial safety data in Q1 2027 and topline results later in 2027. The AHA presentation on November 8, 2026 may provide additional preclinical durability data. No financial data or guidance was provided in this filing.
Price Chart
Executive Summary
Editas Medicine announced regulatory approval in Australia to initiate the Phase 1/2 Strive clinical trial of EDIT-401, a first-in-human in vivo gene editing therapy for hyperlipidemia. The company also released new preclinical data showing ~90% LDL-C reduction maintained over 10 months in non-human primates, to be presented at AHA Scientific Sessions 2026. Initial safety data is expected in Q1 2027, with topline results later in 2027.
Key Facts
- Received approval to initiate first-in-human Phase 1/2 Strive trial of EDIT-401 in Australia for heterozygous familial hypercholesterolemia
- EDIT-401 is an in vivo gene editing medicine designed to upregulate LDLR expression and reduce LDL-C
- Preclinical data demonstrated approximately 90% mean reduction in LDL-C, Lp(a), and ApoB in non-human primates
- New preclinical data showed ~90% LDL-C reduction maintained over 10 months in an ongoing non-human primate study
- Initial safety and tolerability data expected in Q1 2027; topline safety and efficacy data later in 2027
- Five clinical trial sites selected across Australia and New Zealand; New Zealand submission under review
- New preclinical data to be presented at AHA Scientific Sessions 2026 on November 8, 2026
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage biotech with no approved products or reported revenue in this filing
Risk Factors
- EDIT-401 is an experimental, unapproved investigational drug with no clinical data yet; all data is preclinical
- Clinical trials may fail to demonstrate safety or efficacy in humans; preclinical results may not predict human outcomes
- Regulatory approval in New Zealand is still pending; only Australia is cleared
- Cash runway and financing needs not disclosed in this filing; company may need to raise capital to fund the trial
- No revenue or financial data reported in this filing; pre-revenue stage
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001650664-26-000093 |
| Document: editasmedicinepressrelease.htm | 0001650664-26-000093 |
| Document: 0001650664-26-000093-index-headers.html | 0001650664-26-000093 |
| Document: 0001650664-26-000093-index.html | 0001650664-26-000093 |
| Document: 0001650664-26-000093.txt | 0001650664-26-000093 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 8-K | $2.84 | awaiting T+20 | — | $2.40 (−15.49%) |
Sep 9, 2026 6w ago | EFFECT | $2.77 $2.75 | ▼ −0.72% | ▼ −2.92% | $2.40 (−13.36%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.44 $3.30 | ▲ +35.25% | ▲ +33.35% | $2.40 (−1.64%) |
May 26, 2026 21w ago | 424B5 | $3.57 $2.74 | ▲ +23.25% | ▲ +21.35% | $2.40 (+32.77%) |
May 26, 2026 21w ago | 8-K | $3.57 $2.74 | ▲ +23.25% | ▲ +21.35% | $2.40 (+32.77%) |
May 26, 2026 21w ago | Press Release | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 21w ago | 8-K | $3.08 $2.83 | ▼ −8.12% | ▼ −6.17% | $2.40 (−22.08%) |
May 26, 2026 21w ago | 424B5 | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 21w ago | Press Release | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 21w ago | Press Release | $3.08 $2.83 | ▼ −8.12% | ▼ −6.17% | $2.40 (−22.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers